Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype

Background Anti‐interleukin‐5 (IL‐5) monoclonal antibodies can be used as add‐on biological therapies in allergic and non‐allergic patients with severe eosinophilic asthma. However, within such a therapeutic context real‐life investigations are lacking. Objective Therefore, the aim of the present observational study was to evaluate the effects of mepolizumab in allergic and non‐allergic subjects with severe eosinophilic asthma. Methods Relevant...